Novo's REDEFINE 9: Lower CagriSema Doses Produced About 21% Weight Loss at 68 Weeks in Phase 3
In 309 adults with obesity or overweight and no diabetes, CagriSema 1.7 mg/1.7 mg and 1.0 mg/1.0 mg led to 20.7% and 21.0% average weight loss at 68 weeks if everyone stayed on treatment, versus 2.0% on placebo, Novo Nordisk said at ObesityWeek. Counting everyone regardless of adherence, losses were 19.4% and 18.6% versus 4.6%. The trial was not powered to compare the two doses. Results appeared in The Lancet Diabetes & Endocrinology, and an FDA decision on the 2.4 mg/2.4 mg dose is expected this quarter.